LYEL
Lyell Immunopharma Inc.
$16.66
+$0.13(+0.79%)
58
Overall
60
Value
60
Tech
55
Quality
Market Cap
$321.02M
Volume
11.07K
52W Range
$7.65 - $30.00
Target Price
$11.00
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $10.7M | $84.7M | $130.0K | $61.0K | ||
| Total Revenue | $10.7M | $84.7M | $130.0K | $61.0K | ||
| GROSS PROFIT | ||||||
| Gross Profit | $10.7M | $84.7M | $130.0K | $61.0K | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $225.4M | $271.7M | $247.1M | $358.8M | ||
| Research & Development | $138.7M | $159.2M | $182.9M | $258.8M | ||
| Research Expense | $138.7M | $159.2M | $182.9M | $171.6M | ||
| Selling, General & Administrative | $89.1M | $117.3M | $67.0M | $52.0M | ||
| General & Administrative Expenses | $89.1M | $117.3M | $67.0M | $52.0M | ||
| Salaries & Wages | -- | $81.9M | $47.1M | $33.1M | ||
| Depreciation & Amortization | $13.5M | $18.0M | $20.2M | $19.4M | ||
| Depreciation & Amortization | $13.5M | $18.0M | $20.2M | $19.4M | ||
| Other Operating Expenses | $-2.3M | $-4.8M | $-2.8M | $-3.3M | ||
| OPERATING INCOME | ||||||
| Operating income | $-214.8M | $-187.1M | $-247.0M | $-358.8M | ||
| EBITDA | $-234.7M | $-165.1M | $-214.4M | $-323.4M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $1.2M | $7.1M | $23.5M | $24.1M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $7.1M | $23.5M | $24.1M | ||
| Gain on Sale of Securities | -- | $2.9M | -- | -- | ||
| Other Income/Expense | $36.6M | $-3.1M | $11.1M | $59.6M | ||
| Other Special Charges | $-161.0K | $1.9M | $1.8M | $4.7M | ||
| SPECIAL ITEMS | ||||||
| Restructring And Mn A Income | -- | -- | $5.5M | -- | ||
| Special Income Charges | -- | -- | $-5.5M | -- | ||
| Other Impairment Of Capital Assets | $36.4M | -- | -- | $51.3M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| Pre-Tax Income | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| NET INCOME | ||||||
| Net Income | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| Net Income (Continuing Operations) | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| Net Income (Discontinued Operations) | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| Net Income (Common Stockholders) | $-250.2M | $-183.1M | $-234.6M | $-343.0M | ||
| TOTALS | ||||||
| Total Expenses | $225.4M | $271.7M | $247.1M | $358.8M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $6.8K | $12.4M | $12.5M | $261.5M | ||
| Average Shares Outstanding (Diluted) | $6.8K | $12.4M | $12.5M | $261.5M | ||
| Shares Outstanding | $12.3M | $12.5M | $12.7M | $295.2M | ||
| Basic EPS | $-36.8 | $-14.8 | $-18.6 | $-1.31 | ||
| Basic EPS (Continuing Operations) | $-36.8 | $-14.8 | $-18.6 | $-1.31 | ||
| Diluted EPS | $-36.8 | $-14.8 | $-18.6 | $-1.31 | ||
| Diluted EPS (Continuing Operations) | $-36.8 | $-14.8 | $-18.6 | $-1.31 | ||
| OTHER METRICS | ||||||
| Development Expense | -- | -- | -- | $87.2M | ||
| Gain On Sale Of P P E | $308.0K | -- | -- | -- | ||
| Other Gand A | $89.1M | $117.3M | $67.0M | $52.0M | ||
| Restruct | -- | -- | $5.5M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LYEL | $16.66 | +0.8% | 11.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |